{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T08:16:29Z","timestamp":1788682589234,"version":"build-2803163510"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"DOI":"10.1097\/qai.0b013e318068d1dd","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T07:01:38Z","timestamp":1187334098000},"page":"S57-S65","source":"Crossref","is-referenced-by-count":34,"title":["Hepatitis B in the HIV-Coinfected Patient"],"prefix":"10.1097","volume":"45","author":[{"given":"Yves","family":"Benhamou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl","key":"R1-5-20210131","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection.","volume":"44","author":"Alter","year":"2006","journal-title":"J Hepatol"},{"key":"R2-5-20210131","first-page":"1252","article-title":"Incidence of acute hepatitis B-United States, 1990-2002.","volume":"52","year":"2004","journal-title":"Morb Mort Wkly Rep"},{"key":"R3-5-20210131","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"},{"key":"R4-5-20210131","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/00002030-200405210-00010","article-title":"Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.","volume":"18","author":"Law","year":"2004","journal-title":"AIDS"},{"issue":"Suppl","key":"R6-5-20210131","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jhep.2005.01.002","article-title":"Hepatitis B or hepatitis C and human immunodeficiency virus infection.","volume":"42","author":"Thimme","year":"2005","journal-title":"J Hepatol"},{"key":"R7-5-20210131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.1840070109","article-title":"The influence of HTLV III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers.","volume":"7","author":"Krogsgaard","year":"1987","journal-title":"Hepatology"},{"key":"R8-5-20210131","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/infdis\/160.4.577","article-title":"The effects of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.","volume":"160","author":"Bodsworth","year":"1989","journal-title":"J Infect Dis"},{"key":"R9-5-20210131","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1097\/00002030-200110190-00027","article-title":"Acute hepatitis B by sexual transmission after interruption of lamivudine-containing antiretroviral regimen.","volume":"15","author":"Liuzzi","year":"2001","journal-title":"AIDS"},{"key":"R10-5-20210131","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1086\/377135","article-title":"Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects.","volume":"188","author":"Kellerman","year":"2003","journal-title":"J Infect Dis"},{"key":"R11-5-20210131","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.1840150406","article-title":"Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type-1 and hepatitis B viral replication.","volume":"15","author":"Koblin","year":"1992","journal-title":"Hepatology"},{"key":"R12-5-20210131","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"R13-5-20210131","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(05)62892-9","article-title":"Restoration of immunity to chronic hepatitis B infection in HIV-infected patients on protease inhibitors.","volume":"349","author":"Carr","year":"1997","journal-title":"Lancet"},{"key":"R14-5-20210131","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJM199906033402215","article-title":"Resolution of chronic hepatitis after ritonavir treatment in an HIV infected patient.","volume":"340","author":"Velasco","year":"1999","journal-title":"N Engl J Med"},{"key":"R15-5-20210131","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00126334-200004010-00013","article-title":"Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy.","volume":"23","author":"Piroth","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-5-20210131","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/514750","article-title":"Chronic active hepatitis B exacerbation in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.","volume":"28","author":"Bessesen","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R17-5-20210131","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)00437-4","article-title":"Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy.","volume":"108","author":"Proia","year":"2000","journal-title":"Am J Med"},{"key":"R18-5-20210131","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1086\/317535","article-title":"Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy.","volume":"32","author":"Manegold","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R19-5-20210131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/421386","article-title":"Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as a part of HAART.","volume":"39","author":"Drake","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R20-5-20210131","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the MACS.","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"R21-5-20210131","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00002030-200410210-00008","article-title":"Survival in patients with HIV infection and viral hepatitis B or C: a cohort study.","volume":"18","author":"Bonacini","year":"2004","journal-title":"AIDS"},{"key":"R22-5-20210131","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"R23-5-20210131","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Su J, et al, for the Risk Evaluation of Viral Load Elevation and Associated Liver Disease\/Cancer in HBV (REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"R24-5-20210131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"Suppl","key":"R25-5-20210131","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2005.11.020","article-title":"Assessment of treatment efficacy in HBV infection and disease.","volume":"44","author":"Zoulim","year":"2006","journal-title":"J Hepatol"},{"key":"R26-5-20210131","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus.","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"},{"key":"R27-5-20210131","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/135965350400900506","article-title":"The management of hepatitis B virus\/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections at the price of one drug?","volume":"9","author":"Puoti","year":"2004","journal-title":"Antivir Ther"},{"issue":"Suppl","key":"R28-5-20210131","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jhep.2005.11.015","article-title":"Natural history of chronic hepatitis B in co-infected patients.","volume":"44","author":"Puoti","year":"2006","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"R28A-5-20210131","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1097\/QAI.0b013e318068d151","article-title":"Diagnosis and management of cirrhosis in coinfected patients.","volume":"45","author":"Bonacini","year":"2007","journal-title":"J Aquir Immune Defic Syndr"},{"key":"R29-5-20210131","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/hep.1840150404","article-title":"Interactions between human immunodeficiency virus-1, hepatitis delta and hepatitis B virus infection in 260 chronic carriers of hepatitis B virus.","volume":"15","author":"Housset","year":"1992","journal-title":"Hepatology"},{"issue":"Suppl","key":"R30-5-20210131","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.jhep.2005.11.019","article-title":"Treatment algorithm for chronic hepatitis B in HIV-infected patients.","volume":"44","author":"Benhamou","year":"2006","journal-title":"J Hepatol"},{"key":"R31-5-20210131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1542-3565(03)00312-4","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.","volume":"2","author":"Keeffe","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R32-5-20210131","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"R33-5-20210131","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/jinf.2000.0724","article-title":"Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient.","volume":"41","author":"Neau","year":"2000","journal-title":"J Infect"},{"key":"R34-5-20210131","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/gast.2002.30901","article-title":"Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.","volume":"122","author":"Bonacini","year":"2002","journal-title":"Gastroenterology"},{"key":"R35-5-20210131","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1053\/gast.2001.28586","article-title":"YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient.","volume":"121","author":"Bruno","year":"2001","journal-title":"Gastroenterology"},{"key":"R36-5-20210131","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"R39-5-20210131","first-page":"698A","article-title":"Six month maintenance therapy with 10 mg clevudine maintains the viral suppression and biochemical improvement achieved with six months therapy with 30 mg [abstract LB19].","volume":"44","author":"Chung","year":"2006","journal-title":"Hepatology"},{"key":"R40-5-20210131","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","article-title":"Management of antiviral resistance in patients with chronic hepatitis B.","volume":"9","author":"Locarnini","year":"2004","journal-title":"Antivir Ther"},{"key":"R41-5-20210131","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1128\/JCM.40.10.3729-3734.2002","article-title":"Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.","volume":"40","author":"Lok","year":"2002","journal-title":"J Clin Microbiol"},{"key":"R42-5-20210131","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/jhep.2000.19619","article-title":"Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.","volume":"32","author":"Nafa","year":"2000","journal-title":"Hepatology"},{"key":"R43-5-20210131","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hep.20388","article-title":"A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.","volume":"40","author":"Durantel","year":"2004","journal-title":"Hepatology"},{"key":"R44-5-20210131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2003.07.003","article-title":"In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.","volume":"61","author":"Yang","year":"2004","journal-title":"Antiviral Res"},{"key":"R45-5-20210131","first-page":"533","article-title":"Consensus statement. EASL International Consensus Conference on Hepatitis B, 13-14 September 2002, Geneva, Switzerland.","volume":"38","year":"2003","journal-title":"J Hepatol"},{"key":"R46-5-20210131","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1086\/496921","article-title":"Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box.","volume":"41","author":"Thio","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R47-5-20210131","first-page":"968","article-title":"Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients.","volume":"20","author":"Zylberberg","year":"1996","journal-title":"Gastroenterol Clin Biol"},{"key":"R48-5-20210131","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.1840070417","article-title":"Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV III antibodies to recombinant alpha interferon.","volume":"7","author":"McDonald","year":"1987","journal-title":"Hepatology"},{"key":"R49-5-20210131","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0016-5085(95)90021-7","article-title":"Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population.","volume":"108","author":"Wong","year":"1995","journal-title":"Gastroenterology"},{"key":"R50-5-20210131","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"R52-5-20210131","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-125-9-199611010-00001","article-title":"Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.","volume":"125","author":"Benhamou","year":"1996","journal-title":"Ann Intern Med"},{"key":"R53-5-20210131","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/314942","article-title":"Dual efficacy of lamivudine treatment in human immunodeficiency virus\/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.","volume":"180","author":"Dore","year":"1999","journal-title":"J Infect Dis"},{"key":"R55-5-20210131","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2005.08.020","article-title":"Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.","volume":"44","author":"Benhamou","year":"2006","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R56-5-20210131","first-page":"193A","article-title":"Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naive patients [abstract 70].","volume":"40","author":"Chang","year":"2004","journal-title":"Hepatology"},{"key":"R60-5-20210131","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1572-0241.2002.05819.x","article-title":"Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R63-5-20210131","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2893.2000.00210.x","article-title":"Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"key":"R64-5-20210131","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","article-title":"Pozniak AL, et al, for the 903 and 907 Study Teams. Efficacy of tenofovir DF in antiretroviral therapy-naive and -experienced patients.","volume":"189","author":"Dore","year":"2004","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"R65-5-20210131","doi-asserted-by":"crossref","first-page":"712A","DOI":"10.1016\/S0270-9139(03)81193-X","article-title":"Anti-hepatitis B virus (HBV) activity of tenofovir DF in human immunodeficiency virus (HIV) co-infected patients [abstract].","volume":"38","author":"Benhamou","year":"2003","journal-title":"Hepatology"},{"key":"R66-5-20210131","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.21055","article-title":"Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.","volume":"43","author":"Benhamou","year":"2006","journal-title":"Hepatology"},{"key":"R67-5-20210131","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/hep.21388","article-title":"5127 Team. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.","volume":"44","author":"Peters","year":"2006","journal-title":"Hepatology"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200707012-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T20:37:12Z","timestamp":1684010232000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200707012-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":58,"journal-issue":{"issue":"Supplement 2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318068d1dd","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}